Novo Nordisk wants to keep its crown leading the weight loss drugs pack—despite outlook downgrades and lawsuits, its CFO has a plan | Fortune
When Ozempic and Wegovy launched, their bombshell success was only going to be exclusive to their maker—Novo Nordisk—for a matter of time. While the Danish pharma giant holds…
Read more Novo Nordisk wants to keep its crown leading the weight loss drugs pack—despite outlook downgrades and lawsuits, its CFO has a plan | Fortune